Suitable For Men & Women
FDA, CE, HSA Approved
Regenera Activa is a tool developed and manufactured for clinical application of regenerative procedures using healthy hair cells from same patient to improve areas that requires improvement.
Regenera Activa relies solely on patient’s own ability to yield healthy hair follicles by “triggering” areas on the scalp that has poor hair growth.
Tiny skin samples(2.5mm wide) are extracted comfortably at less prominent & healthy area of the scalp(back of ear).
Collected samples are being processed in Regenera Activa device, where samples will be divided in to absorbable portions.
These healthy samples will be then injected into areas on the scalp that requires improvement in hair growth.
There are more than 6000 patients worldwide that have been treated with this method since April 2015 (more than two years for protocol development).
It is fully compatible, beneficial and recommended.
It stabilizes the progression of androgenetic alopecia and also provides greater vitality to the affected hair.
The only medical contraindication is an active infectious process in the scalp.
Poor results can be observed when androgenetic alopecia courses with very few miniaturized hairs or when the onset or progression of the signs is extremely fast. We may also obtain scarce results when treating a scalp undergoing an inflammation process or with concomitant pathologies such as effluviums.
Yes, you can. These are compatible with RIGENERA.
There is still no scientific evidence to can explain it but research is focused on cellular communication.
Yes, but avoid sea and pools for a week.
Yes, it is always beneficial to reinforce the treatment, even when there is not an urgent need.
Of course, hair follicles remaining in the recipient area can enjoy the benefits of Regenera® treatment.
Yes, indeed. It can be performed a few days before or after the micro graft procedure, although there are some physicians the prefer to do it at the same time for they claim the fall of the grafted follicles is reduced.